Michael Hallensleben

Michael Hallensleben has extensive work experience in the medical field. Michael currently holds the position of Vice Medical Director at Hannover Medical School, a role they have held since February 2019. Prior to this, they served as the Managing Senior Physician in Transfusion Medicine at the same institution starting from October 2017. Additionally, they have been the Head of Transplantation Immunology and Immunogenetics at Hannover Medical School since October 2002. In 2009, they became the CEO of Avalas GmbH.

Michael Hallensleben has a comprehensive education history in the field of medicine. Michael began their educational journey in 1989 at Friedrich Schiller University Jena, where they pursued a degree in Medicine. Their studies lasted until 1995, during which they obtained the degree of Arzt.

Subsequently, Hallensleben continued their medical education at Medizinische Hochschule Hannover, commencing in 1996. Michael completed this phase of their education in 1999, successfully earning the degree of Doctor of Medicine (MD), which further enhanced their medical qualifications.

After a brief break in their formal education, Hallensleben returned to Medizinische Hochschule Hannover, where they pursued additional specialization. Michael completed their studies in 2004 and achieved the degree of Facharzt für Transfusionsmedizin.

Overall, Michael Hallensleben has an extensive education background in the field of medicine, including their degrees in Medicine, Doctor of Medicine, and Facharzt für Transfusionsmedizin.